Celebrities With Breast Cancer: 22 Celebrities Whose Lives Have Been Touched by Breast CancerCelebrities With Breast Cancer: 22 Celebrities Whose Lives Have Been Touched by Breast Cancer
Among them: Celebs who are fighting for their lives, have faced a high-risk diagnosis, or have fought alongside someone they love dearly.
Enhancing breast cancer screening could help save young women’s livesEnhancing breast cancer screening could help save young women’s lives
In Estonia, breast cancer screening is offered from the age of 50, yet one-fifth of first diagnoses occur in younger women. A new clinical study has therefore been conducted to test better ways to detect the disease early.
The VA is making it harder for male veterans with breast cancer to get careThe VA is making it harder for male veterans with breast cancer to get care
Male breast cancer is rare, but studies suggest it’s more common — and more lethal — among veterans. Yet the Veterans Administration is making it harder for veterans with breast cancer to get care.
Breakthrough GLP-1 implant promises major weight-loss benefits for petsBreakthrough GLP-1 implant promises major weight-loss benefits for pets
The world’s first GLP-1 weight loss treatment is being administered for pets on an experimental basis. The first cat was successfully dosed in the MEOW-1 study of OKV-119 – an investigational “ultra-long acting” GLP-1 implant, which, according to a press release, is being developed for weight management in cats. OKAVA Pharmaceuticals, the San Francisco-based manufacturer Read More
After NIH grant cuts, breast cancer research at Harvard slowed, and lab workers leftAfter NIH grant cuts, breast cancer research at Harvard slowed, and lab workers left
Amid NIH funding delays, reversals and uncertainty, a scientist at Harvard who studies breast cancer has lost one-third of her lab employees and wonders if she can continue her research experiments.
FDA Approves GLP-1 Pill for Cardiovascular Risk in Type 2 DiabetesFDA Approves GLP-1 Pill for Cardiovascular Risk in Type 2 Diabetes
The US Food and Drug Administration (FDA) recently approved Novo Nordisk’s oral semaglutide, marketed as Rybelsus, to reduce the risk of major adverse cardiac events in adults with type 2 diabetes who are at high risk of these conditions. The US Food and Drug Administration (FDA) recently approved Novo Nordisk’s oral semaglutide, marketed as Rybelsus, Read More
GLP-1 receptor agonists show little effect on obesity-related cancer riskGLP-1 receptor agonists show little effect on obesity-related cancer risk
1. In this systematic review and meta-analysis, use of glucagon-like peptide-1 receptor agonists (GLP-1RAs) was not associated with a significant change in the risk of thyroid, pancreatic, breast, or kidney cancer. 2. Findings were consistent across subgroups, including by follow-up duration and among trials enrolling patients with type 2 diabetes, overweight or obesity, or both Read More
GLP-1 drugs have ‘little or no effect’ on risk of obesity-related cancers, study suggestsGLP-1 drugs have ‘little or no effect’ on risk of obesity-related cancers, study suggests
Popular weight-loss drugs “probably have little or no effect” on a person’s risk of developing one of the 13 obesity-related cancers, new research suggests. Popular weight-loss drugs “probably have little or no effect” on a person’s risk of developing one of the 13 obesity-related cancers, new research suggests.
GLP-1 receptor agonists likely have little or no effect on obesity-related cancer risk, research showsGLP-1 receptor agonists likely have little or no effect on obesity-related cancer risk, research shows
A systematic review and meta-analysis evaluated the risk for obesity-related cancer associated with glucagon-like peptide-1 receptor agonists (GLP-1RAs) in patients with type 2 diabetes (T2D) or overweight or obesity. A systematic review and meta-analysis evaluated the risk for obesity-related cancer associated with glucagon-like peptide-1 receptor agonists (GLP-1RAs) in patients with type 2 diabetes (T2D) or Read More
Her food cravings vanished on Mounjaro then roared backHer food cravings vanished on Mounjaro then roared back
Deep-brain recordings showed that Mounjaro and Zepbound briefly shut down the craving circuits linked to food noise in a patient with severe obesity. Her obsessive thoughts about food disappeared as the medication quieted the nucleus accumbens, the brain’s reward hub. Deep-brain recordings showed that Mounjaro and Zepbound briefly shut down the craving circuits linked to Read More